{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:55:25Z","timestamp":1786460125140,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This scoping review will examine the available evidence to identify the main outcomes, their definitions, and how they were measured, along with the values, preferences, and experiences, of adult patients with aquaporin-4 immunoglobulin G antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorder (NMOSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>NMOSD encompasses a group of inflammatory central nervous system disorders that cause optic neuritis and myelitis. Therapies have different mechanisms of action, but their efficacy has not been fully compared due to variability of outcomes used in randomized controlled trials. No attention has been paid to the selection of outcomes, and primary and secondary outcomes commonly depend on the researcher\u2019s preferences. This issue could be addressed through core outcome sets (COS) which establish the key outcomes that should be assessed in randomized controlled trials. Such COS are currently lacking, and this review will provide a better understanding of COS for NMOSD to facilitate their further development and standardization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria:<\/jats:title>\n                    <jats:p>The review will consider qualitative and quantitative primary studies, conducted in any clinical context, reporting on adult patients with AQP4-IgG-seropositive NMOSD; exploring outcomes, their definitions, and how they were measured; and examining the values, preferences, and experiences of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The review will follow the JBI methodology for scoping reviews. Databases to be searched will include Cochrane CENTRAL (Ovid), MEDLINE (Ovid), Embase (Ovid), and PsycINFO (EBSCOhost); gray literature (medRxiv) will also be searched. Three reviewers will independently screen titles and abstracts, and then full texts. Data will be extracted using a customized tool. Outcomes will be classified using a taxonomy system. A narrative summary will accompany the tabulated and charted results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review registration:<\/jats:title>\n                    <jats:p>COMET https:\/\/www.comet-initiative.org\/Studies\/Details\/3440).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol registration:<\/jats:title>\n                    <jats:p>OSF https:\/\/osf.io\/knrhc\/<\/jats:p>\n                  <\/jats:sec>","DOI":"10.11124\/jbies-25-00456","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:01:30Z","timestamp":1781532090000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Toward a definition of a core outcome set in neuromyelitis optica spectrum disorder: a scoping review protocol"],"prefix":"10.11124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-6301","authenticated-orcid":false,"given":"Cristian E.","family":"Navarro","sequence":"first","affiliation":[{"name":"School of Medicine, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-5307","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"Zuluaga","sequence":"additional","affiliation":[{"name":"Demyelinating Diseases Unit, Medicarte S.A, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-9646","authenticated-orcid":false,"given":"Sarah L.","family":"Gorst","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, University of Liverpool, Liverpool, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-4989","authenticated-orcid":false,"given":"Carlos Enrique","family":"Yepes-Delgado","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad de Antioquia, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-5657","authenticated-orcid":false,"given":"Mateo","family":"Chvatal-Medina","sequence":"additional","affiliation":[{"name":"Grupo Gastrohepatolog\u00eda, School of Medicine, Universidad de Antioquia, Medell\u00edn, Colombia"},{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-9797","authenticated-orcid":false,"given":"Heider","family":"Bautista-Mier","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad de Antioquia, Medell\u00edn, Colombia"},{"name":"Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-8932","authenticated-orcid":false,"given":"Ivan D.","family":"Florez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Antioquia, Medell\u00edn, Colombia"},{"name":"School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada"},{"name":"Pediatric Intensive Care Unit, Cl\u00ednica Las Americas-AUNA, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"R1-20260615","first-page":"177-89","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurol"},{"issue":"6","key":"R2-20260615","doi-asserted-by":"crossref","first-page":"535-44","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"R3-20260615","doi-asserted-by":"crossref","first-page":"445-50","DOI":"10.1590\/0004-282X20140032","article-title":"Seronegative neuromyelitis optica spectrum - the challenges on disease definition and pathogenesis","volume":"72","author":"Sato","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"issue":"11-12","key":"R4-20260615","doi-asserted-by":"crossref","first-page":"1353-62","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult Scler J"},{"issue":"2","key":"R5-20260615","first-page":"59-77","article-title":"Worldwide incidence and prevalence of neuromyelitis optica","volume":"96","author":"Papp","year":"2021","journal-title":"Neurol"},{"issue":"7","key":"R6-20260615","doi-asserted-by":"crossref","first-page":"845-53","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler J"},{"issue":"4","key":"R7-20260615","doi-asserted-by":"crossref","first-page":"344-81","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol"},{"issue":"2","key":"R8-20260615","doi-asserted-by":"crossref","first-page":"767-83","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol Ther"},{"key":"R9-20260615","doi-asserted-by":"crossref","first-page":"105376","DOI":"10.1016\/j.msard.2023.105376","article-title":"Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia","volume":"82","author":"Gil-Rojas","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"R10-20260615","doi-asserted-by":"crossref","first-page":"2950-63","DOI":"10.1007\/s00415-023-11641-1","article-title":"Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis","volume":"270","author":"Yin","year":"2023","journal-title":"J Neurol"},{"issue":"S3","key":"R11-20260615","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"issue":"5","key":"R12-20260615","doi-asserted-by":"crossref","first-page":"515-24","DOI":"10.1191\/0962280205sm415oa","article-title":"Outcome selection bias in meta-analysis","volume":"14","author":"Williamson","year":"2005","journal-title":"Stat Methods Med Res"},{"key":"R13-20260615","doi-asserted-by":"crossref","first-page":"114-23","DOI":"10.1016\/j.jclinepi.2020.09.029","article-title":"A systematic review finds Core Outcome Set uptake varies widely across different areas of health","volume":"129","author":"Hughes","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R14-20260615","doi-asserted-by":"crossref","first-page":"111311","DOI":"10.1016\/j.jclinepi.2024.111311","article-title":"Representation of published core outcome sets in practice guidelines","volume":"169","author":"Rhodes","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"R15-20260615","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13643-016-0188-6","article-title":"Core outcome sets and systematic reviews","volume":"5","author":"Clarke","year":"2016","journal-title":"Syst Rev"},{"issue":"1","key":"R16-20260615","doi-asserted-by":"crossref","first-page":"e0244878","DOI":"10.1371\/journal.pone.0244878","article-title":"Choosing important health outcomes for comparative effectiveness research: 6th annual update to a systematic review of core outcome sets for research","volume":"16","author":"Gargon","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"R17-20260615","doi-asserted-by":"crossref","first-page":"e036562","DOI":"10.1136\/bmjopen-2019-036562","article-title":"Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes to measure in research studies) in Cochrane systematic reviews: a review","volume":"10","author":"Williamson","year":"2020","journal-title":"BMJ Open"},{"key":"R18-20260615","doi-asserted-by":"crossref","first-page":"34-43","DOI":"10.1016\/j.jclinepi.2023.03.011","article-title":"A systematic review of studies reporting the development of core outcome sets for use in routine care","volume":"158","author":"Kearney","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"R19-20260615","doi-asserted-by":"crossref","first-page":"e12026","DOI":"10.1002\/gin2.12026","article-title":"Editorial: the relevance of core outcome sets to clinical guideline development","volume":"1","author":"Rhodes","year":"2024","journal-title":"Clin Pub Health Guidelines"},{"issue":"9","key":"R20-20260615","doi-asserted-by":"crossref","first-page":"1313-22","DOI":"10.1007\/s10067-014-2728-6","article-title":"How well are the ASAS\/OMERACT core outcome sets for ankylosing spondylitis implemented in randomized clinical trials? A systematic literature review","volume":"33","author":"Bautista-Molano","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"R21-20260615","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1745-6215-14-324","article-title":"Outcome measures in rheumatoid arthritis randomised trials over the last 50 years","volume":"14","author":"Kirkham","year":"2013","journal-title":"Trials"},{"issue":"1","key":"R22-20260615","doi-asserted-by":"crossref","first-page":"3-18","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"R23-20260615","doi-asserted-by":"crossref","first-page":"19-34","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"R24-20260615","doi-asserted-by":"crossref","first-page":"e000233","DOI":"10.1136\/bmjmed-2022-000233","article-title":"Comparison of published core outcome sets with outcomes recommended in regulatory guidance from the US Food and Drug Administration and European Medicines Agency: cross sectional analysis","volume":"1","author":"Saldanha","year":"2022","journal-title":"BMJ Med"},{"issue":"17","key":"R25-20260615","first-page":"1805-15","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurol"},{"key":"R26-20260615","first-page":"32-40","article-title":"E.U. paediatric MOG consortium consensus: part 4 \u2013 outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"R27-20260615","doi-asserted-by":"crossref","first-page":"104461","DOI":"10.1016\/j.msard.2022.104461","article-title":"Development of an international, multidisciplinary, patient-centered Standard Outcome Set for Multiple Sclerosis: the S.O.S.MS project","volume":"69","author":"Daniels","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"R29-20260615","doi-asserted-by":"crossref","first-page":"467-73","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"R30-20260615","doi-asserted-by":"crossref","first-page":"40-6","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R31-20260615","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R32-20260615","doi-asserted-by":"crossref","first-page":"84-92","DOI":"10.1016\/j.jclinepi.2017.12.020","article-title":"A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery","volume":"96","author":"Dodd","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"R33-20260615","doi-asserted-by":"crossref","first-page":"110-20","DOI":"10.1016\/j.jclinepi.2018.12.010","article-title":"Higher number of items associated with significantly lower response rates in COS Delphi surveys","volume":"108","author":"Gargon","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"R34-20260615","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-25-00456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:32:42Z","timestamp":1786451562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBIES-25-00456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"URL":"https:\/\/doi.org\/10.11124\/jbies-25-00456","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}